Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Patients With Triple-Negative Breast Cancer Subtypes Based on Genomic, Transcriptomic, Proteomic, and Immune Profiling Data

NCT06833723 is registered in ClinicalTrials.gov with Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences as lead sponsor.

NCT NCT06833723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06833723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Patients With Triple-Negative Breast Cancer Subtypes Based on Genomic, Transcriptomic, Proteomic, and Immune Profiling Data
Lead sponsor
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Phase
Observational
Overall status
Active, not recruiting
Start date
April 17, 2025
Completion date
November 17, 2027
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms